Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes

Diabetes Care

Volumn 23, Issue 2, 2000, Pages 157-162

  Pieber, Thomas R ^a   Eugène Jolchine, Irène ^b   Derobert, Eric ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0343851573     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.2.157     Document Type: Article

References (19)

1. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 7:188-199, 1984
3. Owens DR, Jones IR, Birtwell AJ, Burge CTR, Davies CJ, Heyburn P, Heding LG: Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia 26:261-265, 1984
4. Markussen J, Diers I, Hougaard P, Langkjaer L, Norris K, Snel L, Sørensen AR, Sørensen E, Voigt HO: Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 2:157-166, 1988
5. Brange J, Hansen JF, Langkjaer L, Markussen J, Ribel U, Sørensen AR: Insulin analogues with improved absorption characteristics. Horm Metab Res 26 (Suppl.): 125-130, 1992
6. Seipke G, Geisen K, Neubauer HP, Pittius C: New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia 35 (Suppl 1):A4, 1992
7. Hilgenfeld R, Dörschug M, Geisen K: Controlling insulin bioavailability by crystal contact engineering. Diabetologia 35 (Suppl. 1): A193, 1992
8. Dreyer M, Pein M, Schmidt C, Heidtmann B, Schlünzen M, Roßkamp R: Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31, B32)-human insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 37 (Suppl. 1):A78, 1994
9. Coates PA, Mukherjee S, Luzio S, Srodinski KA, Kurzhals R, Roßkamp R: Pharmacokinetics of a "long-acting" human insulin analogue (HOE 901) in healthy subjects (Abstract). Diabetes 44:A130, 1995
10. Talaulicar M, Willms B, Roßkamp R: Efficacy of HOE 901 following subcutaneous injection for four days in type 1 diabetic subjects (Abstract). Diabetologia 37:A169, 1994
11. Pieber TR, Brunner GA, Siebenhofer A: Insulin analogues. In Diabetes Annual. Vol. 12. Marshall SM, Home PD, Rizza RA, Eds. Elsevier, 1999, p. 255-268
12. Pieber TR, Eugène-Jolchine I, Derobert E, for the European Study Group of HOE 901 in Type 1 Diabetes: Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomized, NPH insulin-controlled trial (Abstract). Diabetes 47:A62, 1998
13. B32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265, 1997
14. Eckel J, Kolter T, Bähr M, Lämmerhirt H, Spelleken M, Seipke G: Growth promoting and metabolic activity of the insulin analogue HOE 901 in muscle cells (Abstract). Diabetologia 38:A4, 1995
15. Liu L, Koenen M, Seipke G, Eckel J: IGF-I receptor-mediated signalling of the human insulin analogue HOE 901 (Abstract). Diabetologia 40:A355, 1997
16. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU: The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp (B10) and regular insulin. Horm Metab Res 30:123-129, 1998
17. Diabetes Control and Complications Trial Research Group: Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 18:1415-1427, 1995
18. Cryer PE: Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 43: 1378-1389, 1994
19. Amiel S: Hypoglycaemia avoidance: technology and knowledge. Lancet 352:502-503, 1998